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Patients with stable disease (SD) following cancer treat-
ment have traditionally not been considered responders.
We, and others, have previously shown that SD is an
important response criteria in cancer patients treated with
HD IL-2 immunotherapy [1-5]. Here we summarize find-
ings from 13 sites, including 97 mRCC and 170 mM
patients enrolled in the retrospective cohort of a national
HD IL-2 database (www.proclaimregistry.com). Patients in
the database were enrolled between 2006-2011, in an era
of immune checkpoint inhibitors and targeted therapies.
In metastatic renal cell carcinoma (mRCC) the median
overall survival (mOS) was not reached in patients
assessed to have SD post HD IL-2 (Figure 1). The mOS
was over 2.5 years in patients with stable disease with
metastatic melanoma (mM). The median follow-up for
both diseases was 3 years. We further sought to examine
whether patients with SD after 1 course, received benefit
with additional HD IL-2 treatment. In mRCC patients that
did not respond to treatment but continued onto another
cycle of HD IL-2, the mOS was not reached and was sta-
tistically significant from patients that stopped treatment
(p = 0.0269) (Figure 2).
Discussion
Unlike chemotherapy and targeted therapies, immunother-
apeutics have the unique potential to achieve long lasting
durable responses in cancer. The continual homeostasis
between the immune system and the tumor requires con-
stant immune pressure, and tipping the balance toward the
immune system using immunotherapy may be important.
Registries such as PROCLAIMSM provide data which may
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Figure 1 Time Since First Dose of IL-2, Months.
Figure 2 Time Since First Dose of IL-2, Months.
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guide the optimal sequencing of therapies and/or prioriti-
zation of randomized clinical trials [6].
Conclusion
We conclude that stable disease is durable and should be
considered a valuable end point. Consolidation of this
response with additional HD IL-2 treatment following
SD may be important.
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